SCOTTSDALE, Ariz., Feb. 8, 2010 (GLOBE NEWSWIRE) -- Health Enhancement Products, Inc. (OTCBB:HEPI) today announced Eric C. Holland, MD, PhD, Vice Chair, Translational Research, Department of Neurosurgery; Director, Brain Tumor Center; Emily Tow Jackson Chair in Oncology of Memorial Sloan-Kettering Cancer Center (MSKCC) has joined the Company's Scientific Advisory Board (SAB) effective immediately.
Dr. Holland commented, "As I learn more and more of the unique molecular structure of the PAZ bioactive compound, I have become increasingly more intrigued in helping the company properly develop and expand potential uses of PAZ. There appears to be a number of potential revenue streams that the company may have the opportunity to exploit, from the cholesterol market to inflammation and chemo prevention. I look forward to becoming a critical part of the Company's SAB."
The recently reconstituted and growing SAB is expected to help address a variety of issues regarding the development and applications of the Company's bioactive compound, ProAlgaZyme (PAZ). Dr. Holland is an internationally recognized, board certified, neurosurgeon specializing in the treatment of gliomas, the most common malignant brain tumor in adults, and metastatic brain tumors.
Dr. Holland joined MSKCC in 2001 from MD Anderson Cancer Center, and is now an Attending Physician in the Departments of Neurology and Neurosurgery, a Member in the Cancer Biology and Genetics Program at the Sloan-Kettering Institute. He is also Director of the Brain Tumor Center at MSKCC.
Dr. Holland's research efforts focus primarily on understanding the molecular mechanisms that underlie the development of central nervous system tumors and on developing models of these cancers in mice. While working as a postdoctoral fellow at the National Institutes of Health in the laboratory of Harold Varmus, he helped develop a technique for somatic cell gene transfer, which has been important for creating mouse models of glioma.
Over the years, he has received several awards, including the Searle Scholars Award, the American Brain Tumor Association Research Award, the Peter Steck Memorial Award, the Bressler Scholars Award, and the Seroussi Award. In addition to serving as an ad hoc reviewer for many scientific journals, Dr. Holland is a member of the editorial boards of Virology, Molecular Cancer Research, the Journal of Molecular Medicine, and Neoplasia.
Dr. Holland has studied at Stanford University's School of Medicine; PhD, University of Chicago. He completed his residency at the University of California at Los Angeles School of Medicine. He also completed his fellowship at the National Cancer Institute in Bethesda, MD.
John Gorman of Health Enhancement Products, commented, "We are obviously thrilled to have someone of Dr. Holland's caliber to join our growing Scientific Advisory Board. His immense knowledge of the medical industry and cancer research will bring a wealth of insightful information we will use to develop and expand the use of our PAZ bioactive compound."
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB:HEPI) is a health and wellness company engaged in the development of a dietary supplement product using only pure, all-natural ingredients. The Company's premier product is ProAlgaZyme (PAZ), a liquid product drawn from living algae grown in purified water. The water in which the algae is grown is drawn off, filtered and bottled as ProAlgaZyme.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
For more information, please visit www.heponline.com/">http://www.heponline.com.